KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Income from Continuing Operations: 2017-2024

Historic Income from Continuing Operations for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Dec 2024 value amounting to $5.7 million.

  • Aurinia Pharmaceuticals' Income from Continuing Operations rose 120.53% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 443.39%. This contributed to the annual value of $5.7 million for FY2024, which is 107.36% up from last year.
  • As of FY2024, Aurinia Pharmaceuticals' Income from Continuing Operations stood at $5.7 million, which was up 107.36% from -$78.1 million recorded in FY2023.
  • In the past 5 years, Aurinia Pharmaceuticals' Income from Continuing Operations registered a high of $5.7 million during FY2024, and its lowest value of -$181.0 million during FY2021.
  • Its 3-year average for Income from Continuing Operations is -$60.2 million, with a median of -$78.1 million in 2023.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first slumped by 76.24% in 2021, then soared by 107.36% in 2024.
  • Yearly analysis of 5 years shows Aurinia Pharmaceuticals' Income from Continuing Operations stood at -$102.7 million in 2020, then slumped by 76.24% to -$181.0 million in 2021, then skyrocketed by 40.22% to -$108.2 million in 2022, then increased by 27.83% to -$78.1 million in 2023, then spiked by 107.36% to $5.7 million in 2024.